Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3229087 | 0.85 | CA12 (0.38) | CA12CA1CA2CA9TSHR | |
| SCHEMBL848744 | 0.81 | CA12 (0.40) | CA12CA1CA2CA9TSHR | |
| SCHEMBL7104114 | 0.81 | CA12 (0.40) | CA12CA1CA2CA9TSHR | |
| SCHEMBL17202935 | 0.81 | CA12 (0.35) | CA12CA1CA2CA9TSHR | |
| SCHEMBL1484613 | 0.80 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL17202911 | 0.78 | TSHR (0.40) | CA12CA1CA2CA9TSHR | |
| SCHEMBL25760245 | 0.78 | CA12 (0.38) | CA12CA1CA2CA9TSHR | |
| SCHEMBL13987082 | 0.78 | CA12 (0.38) | CA12CA1CA2CA9TSHR | |
| SCHEMBL17202690 | 0.74 | ALDH1A1 (0.33) | TSHRMAPTKMT2AALDH1A1TDP1 | |
| SCHEMBL11538395 | 0.72 | GAA (0.38) | MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3981839-B1 | COELENTERAZINE ANALOGS FOR USE IN LUCIFERASE-BASED ASSAYS | PROMEGA CORP (US) | 2025-08-20 | — | — | EP | disclosed |
| US-20240059697-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2024-02-22 | — | — | US | disclosed |
| CN-112513188-B | Coelenterazine analogs | 普洛麦格公司 | 2024-01-26 | — | — | CN | disclosed |
| EP-4279490-A2 | CELL IMPERMEABLE COELENTERAZINE ANALOGUES | Promega Corporation (US) | 2023-11-22 | — | — | EP | disclosed |
| US-11807658-B2 | CD73 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| EP-3548492-B1 | CELL IMPERMEABLE COELENTERAZINE ANALOGUES | PROMEGA CORP (US) | 2023-07-05 | — | — | EP | disclosed |
| US-11691976-B2 | Coelenterazine analogues | PROMEGA CORPORATION (US) | 2023-07-04 | — | — | US | disclosed |
| US-11192894-B2 | Cell impermeable coelenterazine analogues | PROMEGA CORPORATION (US) | 2021-12-07 | — | — | US | disclosed |
| EP-3841173-A1 | COELENTERAZINE ANALOGUES | Promega Corporation (US) | 2021-06-30 | — | — | EP | disclosed |
| CN-112513188-A | Coelenterazine analogs | 普洛麦格公司 | 2021-03-16 | — | — | CN | disclosed |
| US-20200239475-A1 | CELL IMPERMEABLE COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2020-07-30 | — | — | US | disclosed |
| US-10577370-B2 | Cell impermeable coelenterazine analogues | PROMEGA CORPORATION (US) | 2020-03-03 | — | — | US | disclosed |
| US-20200062766-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2020-02-27 | — | — | US | disclosed |
| WO-2020041579-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION (US) | 2020-02-27 | — | — | WO | disclosed |
| EP-3548492-A1 | CELL IMPERMEABLE COELENTERAZINE ANALOGUES | Promega Corporation (US) | 2019-10-09 | — | — | EP | disclosed |
| WO-2018102693-A1 | CELL IMPERMEABLE COELENTERAZINE ANALOGUES | PROMEGA CORPORATION (US) | 2018-06-07 | — | — | WO | disclosed |
| US-20180155350-A1 | CELL IMPERMEABLE COELENTERAZINE ANALOGUES | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2018-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062766-A1 | COELENTERAZINE ANALOGUES | GLB1, SI, TCF7L2 | CA12 1061/4885CA1 2504/4885CA2 2326/4885 |
| US-11192894-B2 | Cell impermeable coelenterazine analogues | SI, GLB1, MRPL21 | CA12 551/4885CA1 853/4885CA2 895/4885 |
| US-11691976-B2 | Coelenterazine analogues | GLB1, SI, TCF7L2 | CA12 1061/4885CA1 2504/4885CA2 2326/4885 |
| US-10577370-B2 | Cell impermeable coelenterazine analogues | SI, GLB1, MRPL21 | CA12 551/4885CA1 853/4885CA2 895/4885 |
| US-20240059697-A1 | COELENTERAZINE ANALOGUES | GLB1, SI, TCF7L2 | CA12 1061/4885CA1 2504/4885CA2 2326/4885 |
| US-20200239475-A1 | CELL IMPERMEABLE COELENTERAZINE ANALOGUES | SI, GLB1, MRPL21 | CA12 551/4885CA1 853/4885CA2 895/4885 |
| US-11807658-B2 | CD73 inhibitors | ENTPD5, NT5E, ENTPD1 | CA12 3586/4885CA1 2856/4885CA2 2826/4885 |
| US-20180155350-A1 | CELL IMPERMEABLE COELENTERAZINE ANALOGUES | SI, GLB1, MRPL21 | CA12 551/4885CA1 853/4885CA2 895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.